Todos Medical Ltd has said that its majority-owned joint venture 3CL Pharma Ltd has once again highlighted the case for its oral dietary supplement Tollovid, pointing to a pre-print in ResearchGate of a study that used the product.
The study, entitled 'Tollovid as a Rescue Agent for Paxlovid Rebound in Acute COVID-19', outlined the case, overseen by Dr Lee Morgentaler in concert with Andrew A. Blumenthal, RN ADS, of a patient with Post-Acute Sequelae of COVID (PASC, or Long COVID) who experienced multiple reinfections with SARS-CoV-2 virus over 27 months.
The patient experienced full COVID symptom resolution with a 5-day course of Paxlovid treatment following positive PCR after which the patient immediately experienced a COVID rebound that was resolved following consumption of supplementation with 3CL protease inhibitor immune support dietary supplement Tollovid, the study showed.
READ: Todos Medical partners with Amerimmune Diagnostics on long-COVID biomarker panel
Tollovid and Tollovid Daily are made from natural ingredients that help support and maintain healthy immune function. They also have potent oral 3CL protease inhibition properties and are anti-cytokine therapeutic candidates for the treatment of the group of viruses that includes coronaviruses such as COVID-19 and MERS.
Tollovir has successfully completed a phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
The full report can be viewed HERE.
Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, with NLC Pharma in March, 2022. Through Todos' brand, 3CL Pharma has commercialized Tollovid in the United States.
Contact the author at giles@proactiveinvestors.com